-
Lemtrada Use Restrictions Issued By EMA’s Pharmacovigilance Risk Assessment Committee Due To Safety Issues
Action Due To Reports Of Lemtrada Side Effects Including Deaths Related To Immune Complications And Heart Or Circulatory Disorders (Posted by Tom Lamb at DrugInjuryWatch.com) In late October 2019 the Pharmacovigilance Risk…
-
Uloric Side Effects Lead To An Increased Risk of Patient Cardiovascular Deaths, Says Health Canada
Drug Safety Warning: Watch For Myocardial Infarction, Stroke, And Cardiac Failure In People Who Are Taking Uloric (Posted by Tom Lamb at DrugInjuryWatch.com) In early November 2019 Health Canada warned that in…
-
European Medicines Agency (EMA) Warns Xeljanz Increases Risk Of Pulmonary Embolism (PE) And Deep Vein Thrombosis (DVT)
Recommends That Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots As Well Aa In Patients Older Than 65 Years Of Age (Posted by Tom Lamb at DrugInjuryWatch.com)…
-
Patients Treated With Imbruvica Had Increased Rate Of Fatal Cardiac Events Compared To Conventional Chemotherapy
Cardiovascular Adverse Drug Reactions Often Occurred Soon After Administration Of Imbruvica, According To Recent Medical Study (Posted by Tom Lamb at DrugInjuryWatch.com) Patients treated with Imbruvica (ibrutinib) had an increased occurrence of…
-
Lemtrada Adverse Events May Occur More Frequently Than Previously Noted By Drug Safety Regulators And Researchers
Ten Deaths Identified As Being Most Probably Related To Lemtrada, With Six Of These Cases Not Previously Reported, According To New Study (Posted by Tom Lamb at DrugInjuryWatch.com) UPDATE: "Dear Healthcare Professional…